Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation

Europace

Volumn 14, Issue 5, 2012, Pages 741-744

  Lip, Gregory Y H ^a   Proclemer, Alessandro ^b   Dagres, Nikolaus ^c   Bongiorni, Maria Grazia ^d   Lewalter, Thorsten ^e   Blomstrom Lundqvist, Carina ^f  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e Isarklinikum Munich   (Germany)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

Ablation; Anticoagulation; Atrial fibrillation; Devices; Pacemakers

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN; HEPARIN; RIVAROXABAN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CORONARY ARTERY DISEASE; DEFIBRILLATOR; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACEMAKER; HEART VALVE PROSTHESIS; HEMATOMA; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; RISK FACTOR; STENT; STROKE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT RESPONSE; WOUND DRAINAGE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER ABLATION; DEFIBRILLATORS, IMPLANTABLE; HEALTH CARE SURVEYS; HUMANS; PROFESSIONAL PRACTICE; RISK ASSESSMENT; RISK FACTORS;

EID: 84860453563     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eus105     Document Type: Article

References (19)

1. Blanc JJ, Almendral J, Brignole M, Fatemi M, Gjesdal K, González-Torrecilla E et al. Scientific Initiatives Committee of the European Heart Rhythm Association. Consensus document on antithrombotic therapy in the setting of electrophysiological procedures. Europace 2008;10:513-27.
2. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 2010;12: 1360-420.
3. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010;137:263-72.
4. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093-100.
5. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ et al. HRS/EHRA/ECAS Expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation Developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and Approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace 2007;9:335-7.
6. Abhishek F, Heist EK, Barrett C et al. Effectiveness of a strategy to reduce major vascular complications from catheter ablation of atrial fibrillation. J Interv Card Electrophysiol 2011;30:211-5.
7. Hoyt H, Bhonsale A, Chilukuri K et al. Complications arising from catheter ablation of atrial fibrillation: Temporal trends and predictors. Heart Rhythm 2011.
8. Cappato R, Calkins H, Chen SA et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005;111:1100-5. (Pubitemid 40365469)
9. Wazni OM, Beheiry S, Fahmy T et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: Comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007;116:2531-4. (Pubitemid 350179218)
10. Schmidt M, Segerson NM, Marschang H et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol 2009;32: 995-9.
11. Kwak JJ, Pak HN, Jang JK et al. Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2010;21:620-5.
12. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. A consensus document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]. Thromb Haemost 2010;103:13-28.
13. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ et al. Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011;106:572-84.
14. Huber K, Airaksinen KJ, Cuisset T, Marin F, Rubboli A, Lip GY. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106:569-71.
15. Stott DJ, Dewar RI, Garratt CJ, Griffith KE, Harding NJ, James MA et al. RCPE UK Consensus Conference on 'Approaching the comprehensive management of atrial fibrillation: Evolution or revolution?'. J R Coll Physicians Edinb 2012;42:34-5.
16. Chao TF, Lin YJ, Tsao HM, Tsai CF, Lin WS, Chang SL et al. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. J Am Coll Cardiol 2011;58:2380-5.
17. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GYH. The value of the CHA2DS2- VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. Thromb Haemost; online publish ahead of print 3 April 2012, doi:10.1160/TH12-03-0175.
18. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010;104:49-60.
19. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2011;E-pub. 20. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation results from a multicenter prospective registry. J Am Coll Cardiol 2012;59:1168-74.